Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
Bylvay missed the study’s primary objective of showing an improvement in native liver survival rates compared to placebo.
The Source
TWSJ
Tech
It’s the Deadliest Room in the House—Especially for Seniors
TWSJ·1d ago·3 min read
Business
SAP Shares Jump After Strong Quarter Reassures Investors of Cloud Business Resilience
TWSJ·23m ago·3 min read
Business
Global Economy Picked Up Before Fresh Energy Hit
TWSJ·32m ago·3 min read
Business
Argan, WDP to Create $14.8 Billion European Logistics Real Estate Group
TWSJ·53m ago·3 min read
Related
On this beat
Health
Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
TWSJ·1h ago·3 min read
Health
Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
TWSJ·2h ago·3 min read
Health
An outbreak of cyclosporiasis that’s sickened thousands shouldn’t prevent you from enjoying a Caesar salad—if you take the right precautions
TWSJ·20h ago·3 min read
Health
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
TWSJ·22h ago·3 min read